You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

NICE recommends Rhythm’s Imcivree to help treat obesity and control hunger

Rhythm Pharmaceuticals has announced that the National Institute for Health and Care Excellence (NICE) has issued guidance that recommends Imcivree – also known as setmelanotide – as an option for treating obesity and controlling hunger caused by pro-opiomelanocortin (POMC) deficiency.